Loss of SYNCRIP unleashes APOBEC-driven mutagenesis, tumor heterogeneity, and AR-targeted therapy resistance in prostate cancer: Cancer Cell
商品説明・詳細
送料・お届け
商品情報
Loss of SYNCRIP unleashes APOBEC-driven mutagenesis, tumor heterogeneity, and AR-targeted therapy resistance in prostate cancer: Cancer Cell,Loss of SYNCRIP unleashes APOBEC-driven mutagenesis, tumor heterogeneity, and AR-targeted therapy resistance in prostate cancer - ScienceDirect,DNMT3B PWWP mutations cause hypermethylation of heterochromatin | EMBO reports,Loss of SYNCRIP unleashes APOBEC-driven mutagenesis, tumor heterogeneity, and AR-targeted therapy resistance in prostate cancer - ScienceDirect,Littleton Independent 092823 by Colorado Community Media - Issuu